Much improvement has been made in the diagnosis and treatment of cancer. However, with ever increasing insight it is also clear that much more needs to be done. Many of these things are within our own hands and actions. Here is a link to an interesting article from NPR with meaningful visuals based on a recent report of the American Cancer Society using data from the Centers for Disease Control and Prevention in Atlanta.

MDOutlook continues delivering timely post-conference insight through the Post-SABCS2014 OncoPoll™ – but with a new dimension this year.

The syndicated MDOutlook post-SABCS2014 analysis focuses on breast cancer therapeutic areas where much new data was presented: new agents, adjuvant & metastatic therapy, and the emerging likelihood of biosimilars used for supportive care.

To insure timely intelligence through our partnership with Oncology Business Review (OBR), field work and analysis was conducted within the month immediately after SABCS. MDOutlook’s global survey response: 125 screened treaters of metastatic breast cancer including a robust number of responses from 15 countries (U.S., each of the EU5, and Rest of Europe).

Your COMPLIMENTARY SABCS2014 Executive Analysis Report delivers key insight on selected topics:

• Current Breast Cancer Patient Volumes – by country & by disease sub-group
• Clinical Assessment of New Agents: Abemaciclib, ANG1005, BMN673, Buparlisib, BYL719, Dalotuzumab, Ipatasertib, MM-302, MPDL3280A, Olaparib, Palbociclib, Pembrolizumab, Taselisib
• Clinical Assessment of New Adjuvant Trial Data
• Outlook on the Use of Biosimilars for the Treatment of Febrile Neutropenia

Click here to receive your COMPLIMENTARY SABCS2014 Executive Analysis Report which includes a content table of the full report.

Our full Post-SABCS2014 report expands on these topics and delivers much more – including the impact of selected SABCS data announcements on physician awareness, their clinical assessment of the potential impact of these therapies & projected future clinical utilization. The full report includes 82 content slides, with 90 graphs and tables. Each slide provides conclusions and insight. If desired, an executive analysis can be included in the report at no extra cost.

If you are interested to learn more or wish to purchase the report, please download the SABCS Syndicated Report Fact Sheet. The purchase price includes an unlimited license to the report for your organization. Tailored analyses and or purchasing of specific modules is available.

Contact us via email or +1.404.496.4136 to order your copy today.

MDOutlook continues its tradition of delivering timely post-conference insight through a series of 3 Post-ASH OncoPolls™ – but with a new dimension.

The syndicated MDOutlook post-ASH2014 analysis focuses on three disease areas where much new data was presented (CLL and ALL, as well as Multiple Myeloma). To insure timely intelligence through our partnership with Oncology Business Review (OBR), field work and analysis was conducted within the month immediately after ASH.

MDOutlook’s global survey response: 329 screened treaters with a robust number of responses from 35 countries, including U.S., each of the EU5 and sub regions of Rest of Europe & Rest of World.

The FREE ASH2014 Executive Analysis Report delivers key insight on selected topics:

• Current Patient Volumes – by country and by disease sub-group / sub-types
• CLL
  Clinical assessment & impact of the concept of Anti-CD20 Antibodies Maintenance Therapy; Tyrosine Kinase Inhibitors; and New Agents: ABT-199, Dinaciclib, Duvelisib, Bendamustine, Ofatumumab and High-Dose Methylprednisolone Combo
• ALL
  Clinical assessment & impact of Immunotherapy and new treatment regimens for Residual Disease, Adult / Young Adult Patients and Older Patients
• Multiple Myeloma
  Clinical assessment & impact of new treatment regimens for New and Relapsed patients

Click here to receive your COMPLIMENTARY ASH2014 Executive Analysis Report which includes a content table of the full report.

Our full syndicated Post-ASH analysis report expands on these topics and delivers much more – including the impact of selected ASH data announcements on physician awareness, their clinical assessment of the potential impact of these therapies & projected future clinical utilization. The full report includes 83 content slides, with 91 graphs and tables. Each slide has conclusions and insight provided. If desired, an executive analysis can be included in the report at no extra cost.

If you are interested to learn more or wish to purchase the report, please download the ASH14 fact sheet here. The purchase price includes an unlimited license to the report for your organization. Tailored analyses and or purchasing of specific modules is available.

Contact us via email or +1.404.496.4136 to order your copy today.